Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
about
Treating childhood acute lymphoblastic leukemia without cranial irradiationCrystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase IL-asparaginase in the treatment of patients with acute lymphoblastic leukemiaNon-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadDevelopment of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringStructural and functional insights into Erwinia carotovora L-asparaginaseElucidation of the Specific Function of the Conserved Threonine Triad Responsible for Human l-Asparaginase Autocleavage and Substrate HydrolysisCurrent applications and different approaches for microbial l-asparaginase productionPurification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous propertiesRecent new drug approvals. Part 1: drugs with pediatric indicationsTailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavageA randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 studyHuman 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain that is allosterically regulated by L-asparagine.Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftHealth-related quality of life among children with acute lymphoblastic leukemia.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseThe toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Isolation and screening of endophytes from the rhizomes of some Zingiberaceae plants for L-asparaginase production.Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaMesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?Inherited genetic variation in childhood acute lymphoblastic leukemia.Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.Outcomes after induction failure in childhood acute lymphoblastic leukemia.Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli.Childhood acute lymphoblastic leukaemia and relapse.Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapyThrombosis and acute lymphoblastic leukaemia.Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitisL-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.
P2860
Q24644599-B8219D08-408F-4C59-83F7-D2021E31BE0EQ24681679-5ADE07B2-28C3-4613-B3AA-F3406932E8ABQ26738640-2E912CC4-B616-4F66-BDF2-D1DD97D6DF7EQ26797513-B9ADF908-9DDC-407D-9036-AF73C28C00FFQ26825970-1AE92982-E9C9-464E-BB9D-4679B19AFE2CQ27026476-98E8707F-01A5-4855-99D0-C5238820D2CDQ27651289-90C4F294-D2F9-4F37-AA14-103D74649867Q27683557-58F33C26-03BE-45D0-B25B-DFD081BCF25DQ28072068-6DE21FC7-CB85-4702-8E6E-37D3BF6C6CDFQ28539475-0CDCC192-ECF9-4B09-A130-A5638F331C5EQ28709081-31120F3D-E43D-4253-A975-2427A214548AQ33274867-D67387CF-D0FD-4ACE-87F4-D0685890D4ACQ33392436-3A39FFAB-EC1C-4F1E-A6EC-50F8E1342691Q33676522-5D04CB16-78FA-4F1A-AD8F-CC3AD6598CE4Q33786540-00D6F40F-0870-4EEC-9119-BE4B317944DDQ34010387-4499425E-E0CA-48A5-AE8F-FC42FA80E4F7Q34400424-24A8E21E-039B-4B40-8238-726B23836C60Q34463641-71DDE61F-7B13-4645-BCA0-49394F640D85Q34644733-7AA19D42-C3FD-40DE-9E78-A0512538B508Q34679298-D11230DA-BD38-41E8-AE15-F490566156E1Q35591960-27B8E45E-D1BA-46DF-B81C-20BC1EAB367AQ35616085-E662EDD8-16A3-47A2-A19B-9F87DB325047Q35677647-937BB549-B74E-4ABD-82AF-E286E745F5D9Q35732108-109DB7F1-323A-4298-A067-BAC03252BE89Q35784497-9ACFC3A2-F662-4A78-B7A5-49A720E29E6CQ35849716-C90BDBE9-3095-4D9E-8AB3-7C87CEFA3B03Q35930217-6661FD3C-204F-4ABA-A37C-FF8A3793FEF1Q36029619-5698DD3E-86CD-41F1-85D0-F5511477D9F9Q36038158-44D063A0-6B2E-4995-902E-8D95346D747DQ36340652-B382821B-4CA9-4D0D-9C9F-3C295CFDDC56Q36697877-46230DDC-AF14-41C5-89A6-7A305CBE3061Q36762608-87D3A0DD-D76E-47FF-B64A-10DC0B55F621Q36805855-74EE2696-0BEF-4D82-B6CC-2F65AFAED348Q36869374-5572AE55-A14D-42BC-8D2B-321B4729F674Q36996143-81BBCF83-6E40-452A-9933-2BEC54ED92C5Q37046992-5059BE55-0168-4D2A-A2E9-DCFC44A65410Q37291435-18E674EB-42C4-4A76-AD87-CD48B12E252BQ37379199-4990E3D0-10BF-4F50-A6D5-1A2D49A465D9Q37522294-F04AECB0-70A7-42C5-9706-AD201DA968E7Q37586935-C209E920-81E5-4652-A507-5BBE5729C986
P2860
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@ast
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@en
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@nl
type
label
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@ast
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@en
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@nl
prefLabel
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@ast
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@en
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@nl
P2093
P921
P356
P1433
P1476
Comparison of Escherichia coli ...... Leukemia Group phase 3 trial.
@en
P2093
Alain Robert
Alina Ferster
Anne-Marie Manel
Brigitte Nelken
Etienne Vilmer
Jacques Otten
Michel Duval
Noël Philippe
Patrick Lutz
Stefan Suciu
P304
P356
10.1182/BLOOD.V99.8.2734
P407
P577
2002-04-01T00:00:00Z